N. A. Gorbachev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. A. Gorbachev has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail Gur'EVich Poluektov
Sechenov First Moscow State Medical University (Sechenov University)
8 shared publications - M.A. Balabanova
Sechenov First Moscow State Medical University
2 shared publications - A. V. Obukhova
I.M. Sechenov First Moscow Medical University, Ministry of Health of Russia (Sechenov University)
1 shared publication - A.V. Romanenko
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - A.YU. Melnikov
LLC «GUTA CLINIC
1 shared publication - Anastasia Zakharova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- 10 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5)
VIII Russian scientific and practical conference with international participation «Clinical Somnology»
The 8th Russian Scientific and Practical Conference with International Participation, “Clinical Somnology,” held on November 14–15, 2025, in Moscow, brought together leading specialists to discuss current issues in the field of sleep medicine. Participants examined issues related to the diagnosis and treatment of sleep disorders, as well as fundamental aspects of somnology and the latest trends in the field. The event, which attracted more than 300 experts from Russia and CIS countries, featured over 70 presentations.
- 10 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5)
VIII Russian scientific and practical conference with international participation «Clinical Somnology»
The 8th Russian Scientific and Practical Conference with International Participation, “Clinical Somnology,” held on November 14–15, 2025, in Moscow, brought together leading specialists to discuss current issues in the field of sleep medicine. Participants examined issues related to the diagnosis and treatment of sleep disorders, as well as fundamental aspects of somnology and the latest trends in the field. The event, which attracted more than 300 experts from Russia and CIS countries, featured over 70 presentations.
- 10 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 55-62
Pharmacological and non-pharmacological treatment for narcolepsy
This paper presents an overview of current pharmacological and non-pharmacological treatment options available for narcolepsy. Antidepressant medications, including selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors, have demonstrated efficacy in mitigating cataplexy episodes. Additionally, various pharmaceutical agents, including psychostimulants and anesthetics, are effective in alleviating excessive daytime sleepiness. Among the behavioral interventions for narcolepsy, adherence to a consistent sleep schedule and the incorporation of scheduled naps throughout the day remain the most widely implemented strategies.
- 10 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 55-62
Pharmacological and non-pharmacological treatment for narcolepsy
This paper presents an overview of current pharmacological and non-pharmacological treatment options available for narcolepsy. Antidepressant medications, including selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors, have demonstrated efficacy in mitigating cataplexy episodes. Additionally, various pharmaceutical agents, including psychostimulants and anesthetics, are effective in alleviating excessive daytime sleepiness. Among the behavioral interventions for narcolepsy, adherence to a consistent sleep schedule and the incorporation of scheduled naps throughout the day remain the most widely implemented strategies.
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 7-11
Current issues of diagnosis and therapy of patients with restless legs syndrome
Current issues in the management of patients with restless legs syndrome are presented. For a clearer understanding of the disease pathogenesis, insights into well-studied components of pathophysiology are provided. The diagnosis is based on criteria developed and published by the International Restless Legs Syndrome Study Group in 2014. Despite the rapid and significant reduction in disease symptoms achieved during pharmacotherapy, tailoring an optimal treatment regimen remains a challenging clinical task, especially in elderly patients due to prolonged use of drugs and, as a result, the low effectiveness of pathogenetic therapy. To improve the condition, it is permitted to divide the daily dose of the drug or discontinue it and replace it with an agent from a different group. Several studies suggested non-drug methods as adjunctive therapy.
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 7-11
Current issues of diagnosis and therapy of patients with restless legs syndrome
Current issues in the management of patients with restless legs syndrome are presented. For a clearer understanding of the disease pathogenesis, insights into well-studied components of pathophysiology are provided. The diagnosis is based on criteria developed and published by the International Restless Legs Syndrome Study Group in 2014. Despite the rapid and significant reduction in disease symptoms achieved during pharmacotherapy, tailoring an optimal treatment regimen remains a challenging clinical task, especially in elderly patients due to prolonged use of drugs and, as a result, the low effectiveness of pathogenetic therapy. To improve the condition, it is permitted to divide the daily dose of the drug or discontinue it and replace it with an agent from a different group. Several studies suggested non-drug methods as adjunctive therapy.
- 1 November 2025
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 55 (9) , 1630-1634
The Use of Zolpidem in the Treatment of Acute and Chronic Insomnia
- 1 November 2025
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 55 (9) , 1630-1634
The Use of Zolpidem in the Treatment of Acute and Chronic Insomnia
- 15 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 38-45
Consensus of the Russian Society of Sleep Medicine on the real-world application of cognitive-behavioral therapy of insomnia
This consensus was developed to establish the terms, basic concepts, and approaches of non-drug treatment of chronic insomnia — cognitive-behavioral therapy of insomnia (CBT-I). The text captures the view of the professional community that both clinical psychologists and psychotherapists, as well as doctors of various specializations with experience in the diagnosis and treatment of sleep disorders, can use CBT-I with the knowledge and skills listed in the relevant section. Indications and contraindications are also listed, and a brief description of behavioral and cognitive techniques, as well as a standard CBT-I protocol, is provided, while the possibility of deviations from it in specific clinical situations is clearly emphasized. The specifics of the method application in special populations and possible therapy formats are also considered.
- 15 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 38-45
Consensus of the Russian Society of Sleep Medicine on the real-world application of cognitive-behavioral therapy of insomnia
This consensus was developed to establish the terms, basic concepts, and approaches of non-drug treatment of chronic insomnia — cognitive-behavioral therapy of insomnia (CBT-I). The text captures the view of the professional community that both clinical psychologists and psychotherapists, as well as doctors of various specializations with experience in the diagnosis and treatment of sleep disorders, can use CBT-I with the knowledge and skills listed in the relevant section. Indications and contraindications are also listed, and a brief description of behavioral and cognitive techniques, as well as a standard CBT-I protocol, is provided, while the possibility of deviations from it in specific clinical situations is clearly emphasized. The specifics of the method application in special populations and possible therapy formats are also considered.
- 15 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 52-56
The use of zolpidem in the treatment of acute and chronic insomnia
The pharmacological features and practice of using the benzodiazepine receptor agonist zolpidem are analyzed. The issues of definition and clinical significance of insomnia in medical practice and the grounds for choosing a class of hypnotic drugs for its treatment are discussed. The main pharmacokinetic and pharmacodynamic properties of zolpidem are described. The data of studies on its effect on subjective and objective sleep parameters, safety and side effects, features of administration to different groups of patients and long-term use (up to 12 months) are presented.
- 15 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 52-56
The use of zolpidem in the treatment of acute and chronic insomnia
The pharmacological features and practice of using the benzodiazepine receptor agonist zolpidem are analyzed. The issues of definition and clinical significance of insomnia in medical practice and the grounds for choosing a class of hypnotic drugs for its treatment are discussed. The main pharmacokinetic and pharmacodynamic properties of zolpidem are described. The data of studies on its effect on subjective and objective sleep parameters, safety and side effects, features of administration to different groups of patients and long-term use (up to 12 months) are presented.
- Open Access
- 21 June 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (3) , 19-25
Clinical and neurophysiological features of the augmentation phenomenon in restless legs syndrome
Anxiety and depressive disorders are common in restless legs syndrome (RLS); in some cases, the disease is accompanied by cognitive impairment and a deterioration in quality of life. The most important treatment method for RLS is the use of dopaminergic medications. In some cases, the use of these drugs leads to a complication - the phenomenon of augmentation, which manifests itself in an increase in RLS symptoms as the dose of medication increases.Objective: to determine the clinical and neurophysiological characteristics of RLS patients with the augmentation phenomenon.Material and methods. 40 patients with RLS were examined: 20 with augmentation (main group, MG; 5 men and 15 women) and 20 without augmentation (comparison group, CG; 7 men and 13 women). The median age of the patients in the MG was 63.5 [56; 71] years, and 62.0 [43.5; 71.5] years in the CG. Clinical assessment was performed using the RLS Severity Rating Scale (RS), Montreal Cognitive Assessment Scale (MoCA), Beck Anxiety Inventory, Beck Depression Inventory, Quality of Life Scale (SF-36), Insomnia Severity Index (ISI), Trail Making Test (Part A), Trail Making Test (part B), phonemic and semantic speech activity tests. All patients underwent suggested immobilization test (SIT) to assess the urge to move on a 10-point numerical rating scale (NRS) and periodic limb movements (PLM) while awake, as well as a polysomnographic examination.Results. Augmentation significantly more frequently resulted in an expansion of the area of distribution of the urge to move and other unpleasant sensations over the entire surface of the legs (p=0.01), painful discomfort in the legs (p=0.001), early onset of symptoms (04:00—18:00; p=0.04), shortening of the latency period for the onset of symptoms (p=0.001), twitching in the legs while awake (p=0.04), taking higher doses of dopaminergic medications (p=0.004). In augmentation, the MoCA score is lower (p=0.01), such patients use fewer words in the semantic speech activity test (p=0.049), have a higher score on the RS (p=0.001) and ISI (p=0.02), a greater number of PLMs while awake according to SIT (p=0.01) compared to CG. No significant differences were found between groups in terms of age, gender, ferritin level, total score on the Beck Anxiety and Depression Inventory, SF-36 Quality of Life Scale, Trail Making Test (Part A), Trail Making Test (part B), phonemic speech activity test, polysomnography indicators (including motor activity during sleep).Conclusion. From a clinical and neurophysiological point of view, the phenomenon of augmentation is not simply a manifestation of a more severe course of RLS but has features that reflect the pathogenesis of this disorder. During augmentation, patients tend to describe the sensations as painful and their involuntary motor activity increases. This reflects changes in the activity of the diencephalospinal tract due to excessive dopaminergic stimulation.
- 21 June 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (3) , 19-25
Open AccessClinical and neurophysiological features of the augmentation phenomenon in restless legs syndrome
Anxiety and depressive disorders are common in restless legs syndrome (RLS); in some cases, the disease is accompanied by cognitive impairment and a deterioration in quality of life. The most important treatment method for RLS is the use of dopaminergic medications. In some cases, the use of these drugs leads to a complication - the phenomenon of augmentation, which manifests itself in an increase in RLS symptoms as the dose of medication increases.Objective: to determine the clinical and neurophysiological characteristics of RLS patients with the augmentation phenomenon.Material and methods. 40 patients with RLS were examined: 20 with augmentation (main group, MG; 5 men and 15 women) and 20 without augmentation (comparison group, CG; 7 men and 13 women). The median age of the patients in the MG was 63.5 [56; 71] years, and 62.0 [43.5; 71.5] years in the CG. Clinical assessment was performed using the RLS Severity Rating Scale (RS), Montreal Cognitive Assessment Scale (MoCA), Beck Anxiety Inventory, Beck Depression Inventory, Quality of Life Scale (SF-36), Insomnia Severity Index (ISI), Trail Making Test (Part A), Trail Making Test (part B), phonemic and semantic speech activity tests. All patients underwent suggested immobilization test (SIT) to assess the urge to move on a 10-point numerical rating scale (NRS) and periodic limb movements (PLM) while awake, as well as a polysomnographic examination.Results. Augmentation significantly more frequently resulted in an expansion of the area of distribution of the urge to move and other unpleasant sensations over the entire surface of the legs (p=0.01), painful discomfort in the legs (p=0.001), early onset of symptoms (04:00—18:00; p=0.04), shortening of the latency period for the onset of symptoms (p=0.001), twitching in the legs while awake (p=0.04), taking higher doses of dopaminergic medications (p=0.004). In augmentation, the MoCA score is lower (p=0.01), such patients use fewer words in the semantic speech activity test (p=0.049), have a higher score on the RS (p=0.001) and ISI (p=0.02), a greater number of PLMs while awake according to SIT (p=0.01) compared to CG. No significant differences were found between groups in terms of age, gender, ferritin level, total score on the Beck Anxiety and Depression Inventory, SF-36 Quality of Life Scale, Trail Making Test (Part A), Trail Making Test (part B), phonemic speech activity test, polysomnography indicators (including motor activity during sleep).Conclusion. From a clinical and neurophysiological point of view, the phenomenon of augmentation is not simply a manifestation of a more severe course of RLS but has features that reflect the pathogenesis of this disorder. During augmentation, patients tend to describe the sensations as painful and their involuntary motor activity increases. This reflects changes in the activity of the diencephalospinal tract due to excessive dopaminergic stimulation.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (2)
Calcitonin gene-related peptide in pathophysiology of migraine
Migraine is one of the most common neurological diseases manifested by headache attacks. Calcitonin-gene related peptide (CGRP) plays a key role in the pathophysiology of migraine. The release of CGRP during a migraine attack leads to cranial vasodilation and neurogenic inflammation. As a result, the sensory fibres of the trigeminal nerve become activated and the transmission of pain impulses to the brain is modulated. Due to the wide representation of CGRP receptors in the brain, the calcitonin-gene related peptide is an actively studied target in studies of antimigraine drugs. This review presents the mechanisms of action, a description of the structure, receptors of the calcitonin gene-related peptide in the pathophysiology of migraine and demonstrates new therapeutic options related to CGRP.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (2)
Calcitonin gene-related peptide in pathophysiology of migraine
Migraine is one of the most common neurological diseases manifested by headache attacks. Calcitonin-gene related peptide (CGRP) plays a key role in the pathophysiology of migraine. The release of CGRP during a migraine attack leads to cranial vasodilation and neurogenic inflammation. As a result, the sensory fibres of the trigeminal nerve become activated and the transmission of pain impulses to the brain is modulated. Due to the wide representation of CGRP receptors in the brain, the calcitonin-gene related peptide is an actively studied target in studies of antimigraine drugs. This review presents the mechanisms of action, a description of the structure, receptors of the calcitonin gene-related peptide in the pathophysiology of migraine and demonstrates new therapeutic options related to CGRP.
- 5 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (5)
XIII Russian scientific and practical conference «Actual problems of somnology»
XIII Russian scientific and practical conference «Actual problems of somnology».
- 5 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (5)
XIII Russian scientific and practical conference «Actual problems of somnology»
XIII Russian scientific and practical conference «Actual problems of somnology».
- Open Access
- 11 April 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 120-124
The use of melatonin preparations in sleep disorders
The role in the body and the biological significance of the pineal hormone melatonin is discussed. Data are presented on the effect on biological rhythms in humans and animals, as well as on the sleep in general. In diurnal humans and animals, melatonin acts on the suprachiasmatic nuclei of the hypothalamus to dampen the wake-stimulating signal of the internal clock, thereby promoting sleep. Data are presented on the clinical use of melatonin in sleep disorders: Circadian Rhythm Sleep-Wake Disorders (jet lag syndrome, delayed sleep phase syndrome, irregular cycle), parasomnias (Rapid-Eye Movements Sleep Behavior Disorder) and insomnia. A significant effect of melatonin preparations with a high level of evidence was confirmed in Circadian Rhythm Sleep-Wake Disorders, less pronounced in Parasomnias. The effects of melatonin, used as a drug for jet lag, have the greatest degree of evidence. The melatonin preparation is recommended to be taken both before the flight and at the new place of stay in accordance with the time of its evening secretion in this time zone. In delayed sleep phase syndrome, the onset of melatonin secretion is delayed, reflecting a general lag in the body’s internal clock. Taking melatonin preparations leads to a shift in the sleep-wake cycle to an earlier time. In REM sleep behavior disorder, melatonin preparations to reduce excessive motor activity are preferred over benzodiazepines, since this disorder manifests itself in people of older age groups, and an undesirable effect on cognitive functions should be avoided. In chronic insomnia, the effect of melatonin significantly exceeds the placebo effect and is most pronounced in people of older age groups.
- 11 April 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 120-124
Open AccessThe use of melatonin preparations in sleep disorders
The role in the body and the biological significance of the pineal hormone melatonin is discussed. Data are presented on the effect on biological rhythms in humans and animals, as well as on the sleep in general. In diurnal humans and animals, melatonin acts on the suprachiasmatic nuclei of the hypothalamus to dampen the wake-stimulating signal of the internal clock, thereby promoting sleep. Data are presented on the clinical use of melatonin in sleep disorders: Circadian Rhythm Sleep-Wake Disorders (jet lag syndrome, delayed sleep phase syndrome, irregular cycle), parasomnias (Rapid-Eye Movements Sleep Behavior Disorder) and insomnia. A significant effect of melatonin preparations with a high level of evidence was confirmed in Circadian Rhythm Sleep-Wake Disorders, less pronounced in Parasomnias. The effects of melatonin, used as a drug for jet lag, have the greatest degree of evidence. The melatonin preparation is recommended to be taken both before the flight and at the new place of stay in accordance with the time of its evening secretion in this time zone. In delayed sleep phase syndrome, the onset of melatonin secretion is delayed, reflecting a general lag in the body’s internal clock. Taking melatonin preparations leads to a shift in the sleep-wake cycle to an earlier time. In REM sleep behavior disorder, melatonin preparations to reduce excessive motor activity are preferred over benzodiazepines, since this disorder manifests itself in people of older age groups, and an undesirable effect on cognitive functions should be avoided. In chronic insomnia, the effect of melatonin significantly exceeds the placebo effect and is most pronounced in people of older age groups.